Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada
Current Oncology · 2024
DOI: 10.3390/curroncol31060264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Qi Guan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Ontario Health, Toronto, ON M5G 2L3, Canada. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Indazoles, Piperidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CADTH.
Abstract (Originalsprache)
Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug’s safety profile in the real world remains uncertain. We conducted a cohort study to describe the patient population using niraparib and the proportion that experienced adverse events between June 2019 and December 2022 in four Canadian provinces (Ontario, Alberta, British Columbia [BC], and Quebec). We used administrative data and electronic medical records from Ontario Health, Alberta Health Services, and BC Cancer, and registry data from Exactis Innovation. We summarized baseline characteristics using descriptive statistics and reported safety outcomes using cumulative incidence. We identified 514 patients receiving niraparib. Mean age was 67 years and most were initiated on a daily dose of 100 or 200 mg/day. Grade 3/4 anemia, neutropenia, and thrombocytopenia occurred in 11–16% of the cohort. In Ontario, the three-month cumulative incidence of grade 3/4 thrombocytopenia was 11.6% (95% CI, 8.3–15.4%), neutropenia was 7.1% (95% CI, 4.6–10.4%), and anemia was 11.3% (95% CI, 8.0–15.2%). Cumulative incidences in the remaining provinces were similar. Initial daily dose and proportions of hematological adverse events were low in the real world and may be related to cautious prescribing and close monitoring by clinicians.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ontario Health, Toronto, ON M5G 2L3, Canada.
- Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada.
- Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada.
- BC Cancer, Vancouver, BC V5Z 4E6, Canada.
- Oncology Outcomes, Calgary, AB T2N 1N4, Canada.
- Alberta Health Services, Edmonton, AB T5J 3E4, Canada.
ORCID-Profile: Reka E Pataky, Stuart Peacock, Scott Gavura, Mina Tadrous
Förderung
- CADTH
Zitieren
APA
Guan, Q., Aktar, S. J., Pataky, R. E., Stephen, M. M., Marques, M., Gambaro, K., Rachedi, K., Forster, K., Strub, S., Stock, D., de Léséleuc, L., Cheung, W. Y., Peacock, S., Farrer, C., Gavura, S., Tadrous, M., Grant, R. C., & Chan, K. K. W. (2024). Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada. Current Oncology. https://doi.org/10.3390/curroncol31060264
Vancouver
Guan Q, Aktar SJ, Pataky RE, Stephen MM, Marques M, Gambaro K, et al. Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada. Current Oncology. 2024. doi:10.3390/curroncol31060264
BibTeX
@article{Guan2024,
author = {Guan, Qi and Aktar, Suriya J and Pataky, Reka E and Stephen, Mariet Mathew and Marques, Maud and Gambaro, Karen and Rachedi, Kahina and Forster, Katharina and Strub, Samara and Stock, David and de Léséleuc, Louis and Cheung, Winson Y and Peacock, Stuart and Farrer, Christie and Gavura, Scott and Tadrous, Mina and Grant, Robert C and Chan, Kelvin K W},
title = {Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada},
journal = {Current Oncology},
year = {2024},
doi = {10.3390/curroncol31060264}
}
EUVIMED